KR100447370B1 - 보호된 (s)-3,4-디히드록시부티르산 에스테르의 개선된 제조 방법 - Google Patents

보호된 (s)-3,4-디히드록시부티르산 에스테르의 개선된 제조 방법 Download PDF

Info

Publication number
KR100447370B1
KR100447370B1 KR10-1999-7000721A KR19997000721A KR100447370B1 KR 100447370 B1 KR100447370 B1 KR 100447370B1 KR 19997000721 A KR19997000721 A KR 19997000721A KR 100447370 B1 KR100447370 B1 KR 100447370B1
Authority
KR
South Korea
Prior art keywords
formula
acid
compound
group
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR10-1999-7000721A
Other languages
English (en)
Korean (ko)
Other versions
KR20000029648A (ko
Inventor
토마스 엘리어트 잭스
도날드 유진 버틀러
Original Assignee
워너-램버트 캄파니 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 워너-램버트 캄파니 엘엘씨 filed Critical 워너-램버트 캄파니 엘엘씨
Publication of KR20000029648A publication Critical patent/KR20000029648A/ko
Application granted granted Critical
Publication of KR100447370B1 publication Critical patent/KR100447370B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/03Preparation of carboxylic acid esters by reacting an ester group with a hydroxy group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/30Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
KR10-1999-7000721A 1996-07-29 1997-07-01 보호된 (s)-3,4-디히드록시부티르산 에스테르의 개선된 제조 방법 Expired - Fee Related KR100447370B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2236996P 1996-07-29 1996-07-29
US60/022,369 1996-07-29

Publications (2)

Publication Number Publication Date
KR20000029648A KR20000029648A (ko) 2000-05-25
KR100447370B1 true KR100447370B1 (ko) 2004-09-08

Family

ID=21809241

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-1999-7000721A Expired - Fee Related KR100447370B1 (ko) 1996-07-29 1997-07-01 보호된 (s)-3,4-디히드록시부티르산 에스테르의 개선된 제조 방법

Country Status (17)

Country Link
US (1) US5998633A (enExample)
EP (1) EP0915866B1 (enExample)
JP (1) JP2000515882A (enExample)
KR (1) KR100447370B1 (enExample)
CN (1) CN1093126C (enExample)
AT (1) ATE215078T1 (enExample)
AU (1) AU3515497A (enExample)
CO (1) CO4950542A1 (enExample)
DE (1) DE69711391T2 (enExample)
DK (1) DK0915866T3 (enExample)
ES (1) ES2176756T3 (enExample)
HU (1) HU226465B1 (enExample)
IL (1) IL127058A (enExample)
PT (1) PT915866E (enExample)
TR (1) TR199900191T2 (enExample)
WO (1) WO1998004543A1 (enExample)
ZA (1) ZA976705B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1093126C (zh) * 1996-07-29 2002-10-23 沃尼尔·朗伯公司 合成被保护的(s)-3,4-二羟基丁酸酯的改进方法
US6713290B2 (en) 1998-07-24 2004-03-30 Samsung Fine Chemicals Co., Ltd. Process for preparing optically pure (S)-3-hydroxy-γ-butyrolactone
KR100332703B1 (ko) * 1998-07-24 2002-08-27 삼성정밀화학 주식회사 광학활성을갖는(s)-3,4-에폭시부티르산염의제조방법
JP2002521031A (ja) 1998-07-24 2002-07-16 サムスン ファイン ケミカルズ カンパニー リミテッド α−(1,4)結合したオリゴサッカリドの製造方法
US6235930B1 (en) * 1999-03-31 2001-05-22 Board Of Trustees Operating Michigan State University Process for the preparation of 3,4-dihydroxybutanoic acid and derivatives thereof from substituted pentose sugars
HU227840B1 (en) * 1999-05-06 2012-05-02 Egis Gyogyszergyar Nyilvanosan M Kod Ruszvunytarsasag Intermediates of atorvastatin synthesis and process for producing them
ES2252088T3 (es) 1999-12-17 2006-05-16 Pfizer Science And Technology Ireland Limited Procedimiento de produccion a escala industrial de la hemisal de calcio de la atorvastatina trihidrato cristalina.
CA2391357C (en) 1999-12-17 2009-01-06 Warner Lambert Research And Development Ireland Limited A process for producing crystalline atorvastatin calcium
JP4598917B2 (ja) * 2000-04-28 2010-12-15 ダイセル化学工業株式会社 ラクトンの製造方法
KR100645665B1 (ko) 2000-07-27 2006-11-13 에스케이 주식회사 (s)-베타-하이드록시-감마-부티로락톤의 연속 제조방법
US6476235B2 (en) 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
EP1734034A3 (en) 2001-01-09 2007-01-03 Warner-Lambert Company LLC Carboxylic acid salts of beta-alanine esters or -amides
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
HUP0400381A2 (hu) * 2001-06-29 2004-09-28 Warner-Lambert Company Llc [R-(R*,R*)]-2-(4fluorfenil)-béta, delta-dihidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)karbonil]-1H-pirrol-1-heptánsav 2:1 arányú kalciumsójának (atorvasztatin) kristályos formái
CA2451159A1 (en) * 2001-07-06 2003-01-16 Teva Pharmaceutical Industries Ltd. Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives
EP1478650B1 (en) * 2002-02-25 2009-09-30 Biocon Limited Novel boronate esters
GB0211716D0 (en) 2002-05-22 2002-07-03 Phoenix Chemicals Ltd Process
CN100357289C (zh) * 2002-08-06 2007-12-26 沃尼尔·朗伯有限责任公司 制备5-(4-氟苯基)-1-[2-((2r,4r)-4-羟基-6-氧代-四氢-吡喃-2-基)乙基]-2-异丙基-4-苯基-1h-吡咯-3-羧酸苯基酰胺的方法
ATE394384T1 (de) * 2002-09-18 2008-05-15 Sk Holdings Co Ltd Kontinuierliches verfahren zur herstellung von optisch reinem (s)-beta hydroxy- gamma- butyrolacton
AU2003263031A1 (en) * 2002-09-20 2004-04-08 Diversa Corporation Chemoenzymatic methods for the synthesis of statins and stain intermediates
US6713639B1 (en) 2002-10-28 2004-03-30 Council Of Scientific And Industrial Research Process for preparing enantiomerically pure (S)-3-hydroxy-gamma-butyrolactone
RS20050760A (sr) * 2003-04-14 2008-04-04 Warner-Lambert Company Llc., Postupak za izradu fenilamida 5-(4- fluorofenil)-1-(2-((2r, 4r)-4-hidroksi- 6-okso-tetrahidro-piran-2-il)etil)-2- izopropil-4-fenil-1h-pirol-3- karboksilne kiseline
US7232920B2 (en) * 2003-04-22 2007-06-19 Biocon Process for stereoselective reduction of β-ketoesters
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20070276027A1 (en) * 2003-09-17 2007-11-29 Warner-Lambert Company Llc Crystalline Forms of [R-(R* ,R*)]-2-(4-Fluorophenyl)-Beta, -Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-[(Phenylamino)Carbonyl]-1H-Pyrrole-1-Heptanoic Acid
WO2005068642A2 (en) 2003-10-01 2005-07-28 Board Of Trustees Operating Michigan State University Bacterial synthesis of 1,2,4-butanetriol enantiomers
AU2005232959A1 (en) * 2004-04-16 2005-10-27 Pfizer Products Inc. Process for forming amorphous atorvastatin calcium
US7875731B2 (en) 2004-05-05 2011-01-25 Pfizer Inc. Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)Carbonyl]-1H-pyrrole-1-heptanoic acid
CA2672554C (en) 2004-07-20 2012-01-03 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl).beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
EP1807055A1 (en) * 2004-10-28 2007-07-18 Warner-Lambert Company LLC Process for forming amorphous atorvastatin
JP2008521878A (ja) * 2004-12-02 2008-06-26 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 非晶質アトルバスタチンの医薬組成物及びその製造のための方法
EP1887005B1 (en) * 2005-05-31 2010-04-21 Kowa Co., Ltd. Processes for production of optically active ppar-activating compounds and intermediates for production thereof
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
DK1957452T3 (da) 2005-11-21 2010-07-26 Warner Lambert Co Nye former af [R-(R*,R*)]-2-(4-fluorphenyl)-B,B-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptansyre- magnesium
US20110165641A1 (en) * 2006-03-31 2011-07-07 The Board Of Trustees Of Michigan State University Synthesis of 1,2,4-Butanetriol Enantiomers from Carbohydrates
CN101512004A (zh) * 2006-07-19 2009-08-19 密歇根州州立大学托管委员会 D-1,2,4-丁三醇的微生物合成
KR100850558B1 (ko) 2008-01-02 2008-08-06 조동옥 아토르바스타틴의 효율적인 제조방법
JP2009256316A (ja) 2008-03-28 2009-11-05 Daicel Chem Ind Ltd β−ヒドロキシ−γ−ブチロラクトンの製造方法
CN101337906B (zh) * 2008-08-15 2012-06-27 河南豫辰精细化工有限公司 一种4-甲基-3-氧代-n-苯基戊酰胺的制备方法
EP2327682A1 (en) 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
SI2373609T1 (sl) 2008-12-19 2013-12-31 Krka, D.D., Novo Mesto Uporaba amfifilnih spojin za kontrolirano kristalizacijo statinov in intermediatov statinov
WO2013004591A1 (en) 2011-07-01 2013-01-10 Dsm Sinochem Pharmaceuticals Netherlands B.V. Micronized crystals of atorvastatin hemicalcium
CN106397241A (zh) * 2016-08-23 2017-02-15 杨锋 一种4‑甲基‑3‑氧代‑n‑苯基戊酰胺的绿色环保后处理方法
CN106588689A (zh) * 2016-12-15 2017-04-26 河南豫辰药业股份有限公司 一种从结晶母液废液中回收阿托伐他汀中间体m4的方法
CN112939901B (zh) * 2021-02-09 2023-05-09 中国科学院福建物质结构研究所 一种α-羟基-γ-丁内酯的制备方法
CN114195670B (zh) * 2021-12-31 2024-03-15 河南豫辰药业股份有限公司 一种阿托伐他汀母核m4的精制方法
CN117447350B (zh) * 2023-10-26 2026-02-13 河南豫辰药业股份有限公司 一种阿托伐他汀m4有机废物综合再利用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2710688B2 (ja) * 1990-10-09 1998-02-10 鐘淵化学工業株式会社 4―ブロモ―3―ヒドロキシ酪酸エステル誘導体の製造法
CA2049536C (en) * 1991-05-13 1999-07-06 Rawle I. Hollingsworth Process for the preparation of 3,4-dihydroxybutanoic acid and salts thereof
JP3351563B2 (ja) * 1992-12-03 2002-11-25 鐘淵化学工業株式会社 3−ヒドロキシ酪酸誘導体の製造法
CN1093126C (zh) * 1996-07-29 2002-10-23 沃尼尔·朗伯公司 合成被保护的(s)-3,4-二羟基丁酸酯的改进方法

Also Published As

Publication number Publication date
CN1093126C (zh) 2002-10-23
HK1020728A1 (en) 2000-05-19
IL127058A0 (en) 1999-09-22
ZA976705B (en) 1998-02-10
PT915866E (pt) 2002-07-31
EP0915866A1 (en) 1999-05-19
DE69711391D1 (de) 2002-05-02
CO4950542A1 (es) 2000-09-01
AU3515497A (en) 1998-02-20
DE69711391T2 (de) 2002-11-07
CN1223647A (zh) 1999-07-21
KR20000029648A (ko) 2000-05-25
TR199900191T2 (xx) 1999-04-21
HUP9904348A3 (en) 2004-03-01
JP2000515882A (ja) 2000-11-28
IL127058A (en) 2001-07-24
EP0915866B1 (en) 2002-03-27
ATE215078T1 (de) 2002-04-15
WO1998004543A1 (en) 1998-02-05
US5998633A (en) 1999-12-07
DK0915866T3 (da) 2002-06-10
ES2176756T3 (es) 2002-12-01
HUP9904348A2 (hu) 2000-04-28
HU226465B1 (en) 2008-12-29

Similar Documents

Publication Publication Date Title
KR100447370B1 (ko) 보호된 (s)-3,4-디히드록시부티르산 에스테르의 개선된 제조 방법
EP1077212B1 (en) Process for producing 6-cyanomethyl-1,3-dioxane-4-acetic acid derivatives
EP2614057B1 (en) Salts of 7-amino-3,5-dihydroxyheptanoic acid esters
WO2003018570A1 (en) Process of lactonization in the preparation of statins
KR100881617B1 (ko) 아토바스타틴 제조를 위한 중간체 및 그의 제조방법
WO2008075165A1 (en) Novel process for the synthesis of [r-(r*, r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid or a pharmaceutically acceptable salt thereof
JP3303327B2 (ja) 不斉誘起触媒
JPH0665226A (ja) (3r,5s)−3,5,6−トリヒドロキシヘキサン酸誘導体及びその製造方法
RU2214407C2 (ru) Усовершенствованный способ лактонизации при получении статинов
KR100367986B1 (ko) 광학활성을 갖는 시아노부탄트리올 유도체 및 그의 제조방법
JP4598917B2 (ja) ラクトンの製造方法
ES2270722B1 (es) Procedimiento para la obtencion de atorvastatina calcica amorfa.
HK1020728B (en) Improved process for the synthesis of protected esters of (s)-3,4-dihydroxybutyric acid
KR100850558B1 (ko) 아토르바스타틴의 효율적인 제조방법
KR100502834B1 (ko) 개선된 락톤화 반응에 의한 심바스타틴의 제조방법 및이의 정제방법
KR100613687B1 (ko) 아토르바스타틴의 제조방법
JPH06102636B2 (ja) N―メチル―3,4―ジメトキシフェニルエチルアミンの新規合成方法
KR100469944B1 (ko) 히드록시테트라히드로퓨란의제조방법
JPH0769960A (ja) 光学活性2−ノルボルナノンの製造方法
JPWO1999057109A1 (ja) 6−シアノメチル−1,3−ジオキサン−4−酢酸誘導体の製造方法
ZA200303734B (en) A lactonization process.
US20130178636A1 (en) Esters of hexanoic acids as intermediates for the preparation of atorvastatin
JPH04316537A (ja) 光学活性3,5−アンチ−ジヒドロキシカルボン酸エステル誘導体

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20080704

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20090827

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20090827

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000